Published on January 10, 2020
- Research updates on navigating CLL treatment option choices
- Safety concerns should patients should think about when choosing treatment
- How to weigh options between fixed duration or long-term treatment
Noted chronic lymphocytic leukemia expert Dr. Jennifer Woyach joined Patient Power as part of our coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. Watch as she provides a report on response and remission duration data from large CLL clinical trials comparing different treatment regimens. Dr. Woyach also describes the advances in understanding the underlying genetics of cancer, and how doctors are tailoring treatment plans to CLL patients.
This program is sponsored by Pharmacyclics and Janssen Biotech. This organization has no editorial control. It is produced by Patient Power, and Patient Power is solely responsible for program content.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.